KWKai-Yun Wang

Kai-Yun Wang

*This is an algorithmically generated author record based on publicly available information.

Kai-Yun Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS

    by Ke-Jie Wang, Xiang-Yu Meng, Jun-Feng Chen, Kai-Yun Wang, Cheng Zhou, Rui Yu, Qi Ma

    Renal cell carcinoma (RCC) is a tumor with unpredictable presentation and poor clinical outcome. RCC is always resistant to chemotherapy and radiation, and weakly sensitive to immunotherapeutic agents. Therefore, novel agents and approaches are urgently needed for the treatment of RCC. Emodin, an anthraquinone compound extracted from rhubarb and other traditional Chinese herbs, has been implicated in a wide variety of pharmacological effects, such as anti‐inflammatory, antiviral, and antitumor activities. However, its role in RCC remains unknown. In this study, we found that emodin effectively killed renal cancer cells without significant toxicity to noncancerous cell HK‐2. Flow cytometry assay with Annexin V‐FITC and PI demonstrated that emodin induces necroptosis, but not apoptosis, in renal cancer cells. Meanwhile, the phosphorylation levels of RIP1 and MLKL, the key necroptosis‐related proteins, were significantly increased. To explore how emodin inhibits kidney tumor growth, we tested reactive oxygen species (ROS) levels and found that the levels of ROS increased upon emodin treatment in a dose‐dependent manner. Further studies demonstrated that emodin induces necroptosis through ROS‐mediated activation of JNK signaling pathway and also inhibits glycolysis by downregulation of GLUT1 through ROS‐mediated inactivation of the PI3K/AKT signaling pathway. Our findings revealed the potential mechanisms by which emodin suppresses renal cancer cell growth and will help develop novel therapeutic approaches for patients with JNK‐ or PI3K/AKT‐dysregulated renal cancer.


    • 28 February 2020
      • Vol. 45  (2) , 187-192

    Progress in applications of 18F-fluciclovine in diagnosis of prostate cancer.

    by Kaiyun Wang, Rui Su, Xiaoyu Sun, Junhui Jiang, Qi Ma

    Prostate cancer is the most common malignancy tumor among men in developed countries. The incidence rate in recent years is also increasing in China. With the development of technology, the application of PET/CT examination has been augmented in the diagnosis of prostate cancer. In order to detect prostate cancer more safely and effectively, new types of targeted tracer for PET/CT has been developed, including 18F-fluiclovine. 18F-fluiclovine has the characteristics of fast uptake, rapid development and fast metabolism, which has a good diagnostic rate for the recurrence and metastasis of prostate cancer. However, at present, there are few researches and its security, diagnosis efficiency, and application value still need further research to verify.